Clinical Trials News

Latest clinical-trials news and updates for US-listed public companies.

📣 Get clinical-trials alerts and analysis

Schrödinger Announces Discontinuation of SGR-2921 Program

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a ...

What is the overall sentiment among institutional investors and short‑seller positions following this announcement? Could the discontinuation trigger any covenant breaches or affect existing financing arrangements? What is the market's perception of Schrödinger's broader platform and its ability to deliver future drug candidates after this failure?
Symbol: SDGR
9 days ago
Read more businesswire

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potentia...

What is the expected impact of the HARMONi trial results on Summit’s valuation multiples relative to peers? Will the data release affect the company’s upcoming earnings guidance or financial outlook? How does the anticipated market size for ivonescimab’s target indication compare to competitors’ pipelines?
Symbol: SMMT
9 days ago
Read more businesswire

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positi...

Are there any upcoming data readouts, additional trial cohorts, or combination therapy studies that could further de‑risk the commercial potential of GFH375? What are the potential pricing strategies for GFH375 in China, and how might they differ from pricing in other regions? Will the positive data trigger any changes in the company’s guidance or financial forecasts?
Symbol: VSTM
10 days ago
Read more businesswire

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fati...

What is the anticipated pricing and reimbursement strategy for Beziterim if approved? How does this trial compare to competitor pipelines targeting Long COVID or related post‑acute infection syndromes? What are the key risks if the trial fails to meet its endpoints?
Symbol: BIVV
10 days ago
Read more globenewswire

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina...

What is the expected reaction from institutional investors and analyst coverage after the data is presented? Could the trial outcomes lead to a re‑rating of the company's valuation by analysts? What are the key regulatory or clinical milestones following the ARROS-1 data release?
Symbol: NUVL
10 days ago
Read more prnewswire

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

What regulatory hurdles could arise if the company seeks to re‑file or modify the trial design? What short‑term trading strategies (e.g., options, short selling) are appropriate given the negative sentiment? How will analyst consensus and target price estimates be revised after this announcement?
Symbol: VDB
10 days ago
Read more businesswire

Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced tha...

Is there any anticipated change in the management’s guidance or communication strategy following the COLLECTiVE202 results? What additional data (e.g., safety, biomarker, subgroup analyses) were disclosed that could affect future strategic decisions? How might this outcome influence the likelihood of a future share‑repurchase program or secondary offering?
Symbol: VENTA
10 days ago
Read more businesswire

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies,...

How does the efficacy and safety data released so far compare to the standard of care and to other emerging regenerative therapies? What are the expected pricing and reimbursement scenarios for a DDD therapy in the U.S. market? How might the news affect short‑interest and options activity on CELZ?
Symbol: CELZ
10 days ago
Read more globenewswire